Back

IgA MAb blocks SARS-CoV-2 Spike-ACE2 interaction providing mucosal immunity

Ejemel, M.; Li, Q.; Hou, S.; Schiller, Z. A.; Wallace, A. L.; Amcheslavsky, A.; Kurt Yilmaz, N.; Toomey, J. R.; Schneider, R.; Close, B. J.; Chen, D.-Y.; Conway, H. L.; Saeed, M.; Cavacini, L. A.; Klempner, M. S.; Schiffer, C. A.; Wang, Y.

2020-05-15 microbiology
10.1101/2020.05.15.096719 bioRxiv
Show abstract

COVID-19 caused by SARS-CoV-2 has become a global pandemic requiring the development of interventions for the prevention or treatment to curtail mortality and morbidity. No vaccine to boost mucosal immunity or as a therapeutic has yet been developed to SARS-CoV-2. In this study we discover and characterize a cross-reactive human IgA monoclonal antibody, MAb362. MAb362 binds to both SARS-CoV and SARS-CoV-2 spike proteins and competitively blocks hACE2 receptor binding, by completely overlapping the hACE2 structural binding epitope. Furthermore, MAb362 IgA neutralizes both pseudotyped SARS-CoV and SARS-CoV-2 in human epithelial cells expressing hACE2. SARS-CoV-2 specific IgA antibodies, such as MAb362, may provide effective immunity against SARS-CoV-2 by inducing mucosal immunity within the respiratory system, a potentially critical feature of an effective vaccine.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Nature Communications
○ 5641 papers in training set
Top 8%
18.8%
Similar papers in this journal
2
Cell Reports
○ 1498 papers in training set
Top 1%
12.1%
Similar papers in this journal
3
Signal Transduction and Targeted Therapy
○ 30 papers in training set
Top 0.1%
9.0%
Similar papers in this journal
4
Cell Host & Microbe
126 papers in training set
Top 0.2%
8.1%
5
Nature
○ 645 papers in training set
Top 2%
8.0%
Similar papers in this journal
50% of probability mass above
6
Cell Research
○ 51 papers in training set
Top 0.1%
5.2%
7
eLife
● 5828 papers in training set
Top 32%
3.6%
8
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 16%
3.2%
9
Structure
○ 193 papers in training set
Top 0.9%
2.7%
10
Nature Structural & Molecular Biology
236 papers in training set
Top 2%
2.7%
11
Immunity
○ 67 papers in training set
Top 0.9%
1.8%
12
Cell Chemical Biology
○ 94 papers in training set
Top 0.8%
1.5%
13
Cell
○ 431 papers in training set
Top 7%
1.5%
14
Communications Biology
○ 993 papers in training set
Top 18%
1.4%
15
Science
● 477 papers in training set
Top 6%
1.4%
16
iScience
○ 1154 papers in training set
Top 25%
1.1%
17
Science Advances
● 1243 papers in training set
Top 24%
1.1%
18
mBio
● 833 papers in training set
Top 9%
1.1%
19
Nature Microbiology
○ 155 papers in training set
Top 2%
1.1%
20
Journal of Virology
● 499 papers in training set
Top 3%
1.1%
21
Cell Discovery
○ 57 papers in training set
Top 0.7%
1.1%
22
PLOS Pathogens
● 820 papers in training set
Top 9%
0.9%
23
Nature Chemical Biology
○ 119 papers in training set
Top 3%
0.9%
24
Cell Reports Medicine
○ 153 papers in training set
Top 6%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.